## Rajan T Gupta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3824662/publications.pdf

Version: 2024-02-01

152 papers 3,716 citations

147801 31 h-index 56 g-index

156 all docs 156 docs citations

156 times ranked

4574 citing authors

#	Article	IF	CITATIONS
1	The SCARD Fellowship Policy and the Abdominal Imaging Fellowship: A Follow-up Survey After the First Year. Academic Radiology, 2022, 29, 287-293.	2.5	6
2	A randomized controlled trial comparing changes in fitness with or without supervised exercise in patients initiated on enzalutamide and androgen deprivation therapy for non-metastatic castration-sensitive prostate cancer (EXTEND). Prostate Cancer and Prostatic Diseases, 2022, 25, 58-64.	3.9	4
3	Guest Editorial for: "Diagnostic Efficiency of Diffusion Sequences and a Clinical Nomogram for Detecting Lymph Node Metastases From Rectal Cancer― Academic Radiology, 2022, 29, 1296-1297.	2.5	2
4	ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update. Journal of the American College of Radiology, 2022, 19, S156-S174.	1.8	2
5	Prostate MRI Qualification: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2022, 219, 691-702.	2.2	16
6	Body composition in patients with metastatic renal cell carcinoma receiving ipilimumab plus nivolumab Journal of Clinical Oncology, 2022, 40, e16517-e16517.	1.6	0
7	Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement. Abdominal Radiology, 2022, 47, 2917-2927.	2.1	6
8	How frequently does hepatocellular carcinoma develop in at-risk patients with a negative liver MRI examination with intravenous Gadobenate dimeglumine?. Abdominal Radiology, 2021, 46, 969-978.	2.1	5
9	Editorial Comment on "Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsyâ€∙ American Journal of Roentgenology, 2021, 216, 690-690.	2.2	0
10	Diet and Exercise Are not Associated with Skeletal Muscle Mass and Sarcopenia in Patients with Bladder Cancer. European Urology Oncology, 2021, 4, 237-245.	5.4	5
11	Can procedure time for paracentesis be optimized based on bottle selection?. Abdominal Radiology, 2021, 46, 4062-4067.	2.1	0
12	Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 781.e17-781.e24.	1.6	10
13	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143) Journal of Clinical Oncology, 2021, 39, TPS4596-TPS4596.	1.6	5
14	ACR Appropriateness Criteria® Renal Failure. Journal of the American College of Radiology, 2021, 18, S174-S188.	1.8	4
15	Pericardial Adipose Tissue Volume and Left Ventricular Assist Device-Associated Outcomes. Journal of Cardiac Failure, 2021, , .	1.7	O
16	Intravascular Ultrasound-Guided Transvenous Biopsy of Abdominal and Pelvic Targets Difficult to Access by Percutaneous Needle Biopsy: Technique and Initial Clinical Experience. Journal of Vascular and Interventional Radiology, 2021, 32, 1310-1318.e2.	0.5	11
17	Past, present, and future of abdominal radiology fellowship recruitment. Abdominal Radiology, 2021, 46, 5462-5465.	2.1	2
18	Artificial Intelligence–assisted Prostate Cancer Diagnosis: Radiologic-Pathologic Correlation. Radiographics, 2021, 41, 1676-1697.	3.3	17

#	Article	lF	Citations
19	ACR Appropriateness Criteria $\hat{A}^{\otimes}$ Adrenal Mass Evaluation: 2021 Update. Journal of the American College of Radiology, 2021, 18, S251-S267.	1.8	11
20	Plâ€RADS: Past, present, and future. Journal of Magnetic Resonance Imaging, 2020, 52, 33-53.	3.4	37
21	Post-treatment prostate MRI. Abdominal Radiology, 2020, 45, 2184-2197.	2.1	14
22	Prospects of a Fellowship Match for Abdominal Imaging: A National Survey by the Society of Abdominal Radiology. Journal of the American College of Radiology, 2020, 17, 804-811.	1.8	7
23	ACR Appropriateness Criteria® Hematuria. Journal of the American College of Radiology, 2020, 17, S138-S147.	1.8	12
24	Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncolmmunology, 2020, 9, 1773200.	4.6	10
25	MRI/TRUS fusion vs. systematic biopsy: intra-patient comparison of diagnostic accuracy for prostate cancer using PI-RADS v2. Abdominal Radiology, 2020, 45, 2235-2243.	2.1	5
26	Esophageal Function Tests are Not Associated with Barium Swallow Findings in Advanced Lung Disease. Dysphagia, 2020, 35, 864-870.	1.8	5
27	PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2020, 18, 509-513.	1.9	1
28	Variability of the Positive Predictive Value of PI-RADS for Prostate MRI across 26 Centers: Experience of the Society of Abdominal Radiology Prostate Cancer Disease-focused Panel. Radiology, 2020, 296, 76-84.	7.3	207
29	ACR Appropriateness Criteria® Indeterminate Renal Mass. Journal of the American College of Radiology, 2020, 17, S415-S428.	1.8	19
30	Association of LRP1B pathogenic genomic alterations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types Journal of Clinical Oncology, 2020, 38, 3007-3007.	1.6	3
31	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143) Journal of Clinical Oncology, 2020, 38, TPS765-TPS765.	1.6	1
32	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143) Journal of Clinical Oncology, 2020, 38, TPS5101-TPS5101.	1.6	3
33	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	2.4	35
34	Clinical utility of FoundationOne tissue molecular profiling in men with metastatic prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 813.e1-813.e9.	1.6	16
35	Pembrolizumab in men with heavily treated metastatic castrateâ€resistant prostate cancer. Cancer Medicine, 2019, 8, 4644-4655.	2.8	55
36	A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. Clinical Genitourinary Cancer, 2019, 17, e672-e677.	1.9	4

#	Article	IF	CITATIONS
37	LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10–19 mm With Arterial Phase Hyperenhancement. American Journal of Roentgenology, 2019, 213, W57-W65.	2.2	28
38	ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer. Journal of the American College of Radiology, 2019, 16, S399-S416.	1.8	7
39	Human–machine partnership with artificial intelligence for chest radiograph diagnosis. Npj Digital Medicine, 2019, 2, 111.	10.9	94
40	Anterior gland focal cryoablation: proof-of-concept primary prostate cancer treatment in select men with localized anterior cancers detected by multi-parametric magnetic resonance imaging. BMC Urology, 2019, 19, 127.	1.4	10
41	The Need for Practical and Accurate Measures of Value for Radiology. Journal of the American College of Radiology, 2019, 16, 810-813.	1.8	7
42	Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies – An alternative template for prostate fusion biopsy. European Journal of Radiology, 2019, 110, 7-13.	2.6	13
43	Magnetic resonance imaging features of pubic symphysis urinary fistula with pubic bone osteomyelitis in the treated prostate cancer patient. Abdominal Radiology, 2019, 44, 1453-1460.	2.1	18
44	A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). Academic Radiology, 2019, 26, 5-14.	2.5	12
45	Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, 2595-2595.	1.6	1
46	Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, e16079-e16079.	1.6	3
47	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143) Journal of Clinical Oncology, 2019, 37, TPS4597-TPS4597.	1.6	3
48	Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2019, 37, 577-577.	1.6	1
49	Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, 589-589.	1.6	5
50	Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, 607-607.	1.6	2
51	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143) Journal of Clinical Oncology, 2019, 37, TPS684-TPS684.	1.6	11
52	Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC) Journal of Clinical Oncology, 2019, 37, 63-63.	1.6	0
53	Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma Journal of Clinical Oncology, 2019, 37, 61-61.	1.6	0
54	Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma Journal of Clinical Oncology, 2019, 37, 62-62.	1.6	2

#	Article	IF	CITATIONS
55	Sarcopenia in bladder cancer patients is an unmodifiable outcomes predictor Journal of Clinical Oncology, 2019, 37, 480-480.	1.6	O
56	Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2019, 37, 400-400.	1.6	0
57	Immune checkpoint inhibitor response in tumors with LRP1B variants Journal of Clinical Oncology, 2019, 37, e14291-e14291.	1.6	O
58	Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC) Journal of Clinical Oncology, 2019, 37, e14259-e14259.	1.6	0
59	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Radiologic Clinics of North America, 2018, 56, 239-250.	1.8	13
60	Progression of Treated versus Untreated Liver Imaging Reporting and Data System Category 4 Masses after Transcatheter Arterial Embolization Therapy. Journal of Vascular and Interventional Radiology, 2018, 29, 598-606.	0.5	3
61	Prostate MRI can be accurate but can variability be reduced?. Nature Reviews Urology, 2018, 15, 339-340.	3.8	2
62	New prostate cancer prognostic grade group (PGG): Can multiparametric MRI (mpMRI) accurately separate patients with low-, intermediate-, and high-grade cancer?. Abdominal Radiology, 2018, 43, 702-712.	2.1	15
63	LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdominal Radiology, 2018, 43, 56-74.	2.1	58
64	Platinum sensitivity in metastatic prostate cancer: does histology matter?. Prostate Cancer and Prostatic Diseases, 2018, 21, 92-99.	3.9	17
65	Correlation Between 3D ARFI and Quantitative Imaging Metrics from SWEI and Multi-Parametric MRI in Vivo in Normal and Cancerous Prostate Tissue. , 2018, , .		0
66	Three-dimensional localization and targeting of prostate cancer foci with imaging and histopathologic correlation. Current Opinion in Urology, 2018, 28, 506-511.	1.8	4
67	Lymphogranuloma venereum (LGV) proctocolitis mimicking rectal lymphoma. Radiology Case Reports, 2018, 13, 1119-1122.	0.6	5
68	Factors Associated With Emergency Department Visits and Hospital Admissions After Invasive Outpatient Procedures in the Veterans Health Administration. JAMA Surgery, 2018, 153, 774.	4.3	3
69	Abdominal Radiography With Digital Tomosynthesis: An Alternative to Computed Tomography for Identification of Urinary Calculi?. Urology, 2018, 120, 56-61.	1.0	5
70	Multiparametric Prostate MR Imaging: Impact on Clinical Staging and Decision Making. Urologic Clinics of North America, 2018, 45, 455-466.	1.8	9
71	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC) Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	1.6	1
72	Can computer-aided diagnosis assist in the identification of prostate cancer on prostate MRI? a multi-center, multi-reader investigation. Oncotarget, 2018, 9, 33804-33817.	1.8	65

#	Article	IF	CITATIONS
73	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143) Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	1.6	0
74	Optimizing Multiparametric Magnetic Resonance Imaging for a Focal Therapy Practice: Quality Improvement. Current Clinical Urology, 2017, , 177-192.	0.0	0
75	Imaging Advances in Urolithiasis. Journal of Endourology, 2017, 31, 623-629.	2.1	9
76	Does mpMRI improve clinical criteria in selecting men with prostate cancer for active surveillance?. Prostate Cancer and Prostatic Diseases, 2017, 20, 323-327.	3.9	16
77	The Contemporary Role of Multiparametric Magnetic Resonance Imaging in Active Surveillance for Prostate Cancer. Current Urology Reports, 2017, 18, 52.	2.2	15
78	Characterization of Small Focal Renal Lesions: Diagnostic Accuracy with Single-Phase Contrast-enhanced Dual-Energy CT with Material Attenuation Analysis Compared with Conventional Attenuation Measurements. Radiology, 2017, 284, 737-747.	7.3	69
79	PD10-11 ANALYSIS OF THE PREDICTIVE UTILITY OF PROGNOSTIC GRADE GROUPS (PGG) FOR PREDICTING PERIOPERATIVE ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY IN THE SHARED EQUAL ACCESS REGIONAL CANCER HOSPITAL (SEARCH) DATABASE. Journal of Urology, 2017, 197, .	0.4	0
80	PD03-10 VALIDATION OF THE 2015 PROSTATE CANCER PROGNOSTIC GRADE GROUPS FOR PREDICTING LONG-TERM ONCOLOGIC OUTCOMES IN A SHARED EQUAL ACCESS HEALTH SYSTEM Journal of Urology, 2017, 197, .	0.4	0
81	Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma. Radiology, 2017, 285, 311-318.	7.3	14
82	MP01-07 THE ADDED UTILITY OF DIGITAL TOMOSYNTHESIS TO STANDARD ABDOMINAL RADIOGRAPHY FOR IDENTIFICATION OF URINARY CALCULI. Journal of Urology, 2017, 197, .	0.4	0
83	Assessing clinically significant prostate cancer: Diagnostic properties of multiparametric magnetic resonance imaging compared to threeâ€dimensional transperineal template mapping histopathology. International Journal of Urology, 2017, 24, 137-143.	1.0	9
84	Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project. World Journal of Urology, 2017, 35, 695-701.	2.2	63
85	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC) Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	1.6	7
86	Association of neuroendocrine phenotype with platinum chemotherapy outcomes in men with metastatic prostate cancer Journal of Clinical Oncology, 2017, 35, e16532-e16532.	1.6	1
87	Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. World Journal of Urology, 2016, 34, 1373-1382.	2.2	62
88	How and why a generation of radiologists must be trained to accurately interpret prostate mpMRI. Abdominal Radiology, 2016, 41, 803-804.	2.1	22
89	Interobserver Reproducibility of the PI-RADS Version 2 Lexicon: A Multicenter Study of Six Experienced Prostate Radiologists. Radiology, 2016, 280, 793-804.	7.3	398
90	Identifying Clinically Significant Prostate Cancers using 3-D InÂVivo Acoustic Radiation Force Impulse Imaging with Whole-Mount Histology Validation. Ultrasound in Medicine and Biology, 2016, 42, 1251-1262.	1.5	38

#	Article	IF	Citations
91	Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?. American Journal of Roentgenology, 2016, 207, 87-95.	2.2	36
92	Comparison between 3D ARFI imaging and mpMRI in detecting clinically-significant prostate cancer lesions. , 2016, , .		1
93	Integration of multiparametric MRI into active surveillance of prostate cancer. Future Oncology, 2016, 12, 2513-2529.	2.4	6
94	Portrayal of radiology in a major medical television series: How does it influence the perception of radiology among patients and radiology professionals?. European Radiology, 2016, 26, 2863-2869.	4.5	8
95	Massive gas gangrene secondary to occult colon carcinoma. Radiology Case Reports, 2016, 11, 67-69.	0.6	6
96	Multiparametric prostate MRI: focus on T2-weighted imaging and role in staging of prostate cancer. Abdominal Radiology, 2016, 41, 831-843.	2.1	22
97	Navigating MRI-TRUS fusion biopsy: optimizing the process and avoiding technical pitfalls. Expert Review of Anticancer Therapy, 2016, 16, 303-311.	2.4	22
98	Defining the Incremental Utility of Prostate Multiparametric Magnetic Resonance Imaging at Standard and Specialized Read in Predicting Extracapsular Extension of Prostate Cancer. European Urology, 2016, 70, 211-213.	1.9	69
99	Changes in skeletal muscle cross sectional area (CSA) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZ) Journal of Clinical Oncology, 2016, 34, e16601-e16601.	1.6	2
100	MP28-05 URETEROSCOPIC REMOVAL OF CALCULUS IN POORLY FUNCTIONING (<10%) KIDNEYS DUE TO URETERIC STONE: AÂPROSPECTIVE OUTCOME ANALYSIS. Journal of Urology, 2015, 193, .	0.4	0
101	Nephrogenic Systemic Fibrosis Risk After Liver Magnetic Resonance Imaging With Gadoxetate Disodium in Patients With Moderate to Severe Renal Impairment. Investigative Radiology, 2015, 50, 416-422.	6.2	44
102	Radiology Reports for Incidental Thyroid Nodules on CT and MRI: High Variability across Subspecialties. American Journal of Neuroradiology, 2015, 36, 397-402.	2.4	33
103	Practice and Quality Improvement: Successful Implementation of TeamSTEPPS Tools Into an Academic Interventional Ultrasound Practice. American Journal of Roentgenology, 2015, 204, 105-110.	2.2	14
104	Computed high b-value diffusion-weighted imaging improves lesion contrast and conspicuity in prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 155-160.	3.9	20
105	Should men with idiopathic obstructive azoospermia be screened for genitourinary tuberculosis?. Journal of Human Reproductive Sciences, 2015, 8, 43.	0.9	8
106	Apparent Diffusion Coefficient Values of the Benign Central Zone of the Prostate: Comparison With Low- and High-Grade Prostate Cancer. American Journal of Roentgenology, 2015, 205, 331-336.	2.2	25
107	Detection of prostate cancer with multiparametric MRI (mpMRI): effect of dedicated reader education on accuracy and confidence of index and anterior cancer diagnosis. Abdominal Imaging, 2015, 40, 134-142.	2.0	71
108	Effect of radiologists' experience with an adaptive statistical iterative reconstruction algorithm on detection of hypervascular liver lesions and perception of image quality. Abdominal Imaging, 2015, 40, 2850-2860.	2.0	5

#	Article	IF	Citations
109	Current Trends and New Frontiers in Focal Therapy for Localized Prostate Cancer. Current Urology Reports, 2015, 16, 35.	2.2	12
110	How the radiologist can add value in the evaluation of the pre- and post-surgical pancreas. Abdominal Imaging, 2015, 40, 2932-2944.	2.0	9
111	B-Mode and Acoustic Radiation Force Impulse (ARFI) Imaging of Prostate Zonal Anatomy. Ultrasonic Imaging, 2015, 37, 22-41.	2.6	19
112	The role of magnetic resonance imaging ( <scp>MRI</scp> ) in focal therapy for prostate cancer: recommendations from a consensus panel. BJU International, 2014, 113, 218-227.	2.5	80
113	Retrospective assessment of the utility of an ironâ€based agent for contrastâ€enhanced magnetic resonance venography in patients with endstage renal diseases. Journal of Magnetic Resonance Imaging, 2014, 40, 113-118.	3.4	46
114	Recent Developments in Multiparametric Prostate MR Imaging. Current Radiology Reports, 2014, 2, 1.	1.4	1
115	MP42-16 COMPARISON OF THE PREDICTIVE ACCURACY OF THE PARTINÂTABLES VS MULTI-PARAMETRIC MRI IN FORECASTING ORGAN-CONFINED PROSTATE CANCER. Journal of Urology, 2014, 191, .	0.4	0
116	Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1292-1299.	1.6	80
117	Multimodality Approach to Detection and Characterization of Hepatic Hemangiomas. , 2014, , 123-144.		0
118	Lesion detection and assessment of extrahepatic findings in abdominal MRI using hepatocyte specific contrast agents – comparison of Gd-EOB-DTPA and Gd-BOPTA. BMC Medical Imaging, 2013, 13, 10.	2.7	2
119	Clinical impact of an adaptive statistical iterative reconstruction algorithm for detection of hypervascular liver tumours using a low tube voltage, high tube current MDCT technique. European Radiology, 2013, 23, 3325-3335.	4.5	32
120	Radiologic-Pathologic Correlation of Uncommon Mesenchymal Liver Tumors. Current Problems in Diagnostic Radiology, 2013, 42, 183-190.	1.4	10
121	Evaluation of the Biliary Tree and Gallbladder With Hepatocellular MR Contrast Agents. Current Problems in Diagnostic Radiology, 2013, 42, 67-76.	1.4	10
122	JOURNAL CLUB: MRI Assessment of Biliary Ductal Obstruction: Is There Added Value of T1-Weighted Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid–Enhanced MR Cholangiography?. American Journal of Roentgenology, 2013, 201, W49-W56.	2.2	20
123	Abdominopelvic and Lower Extremity Deep Venous Thrombosis: Evaluation With Contrast-Enhanced MR Venography With a Blood-Pool Agent. American Journal of Roentgenology, 2013, 201, 208-214.	2.2	20
124	Hepatocellular carcinoma in a North American population: Does hepatobiliary MR imaging with Gdâ€EOBâ€DTPA improve sensitivity and confidence for diagnosis? Journal of Magnetic Resonance Imaging, 2013, 37, 398-406.	3.4	91
125	Quantitative Dynamic Contrast-Enhanced MRI of Pelvic and Lumbar Bone Marrow: Effect of Age and Marrow Fat Content on Pharmacokinetic Parameter Values. American Journal of Roentgenology, 2013, 200, W297-W303.	2.2	29
126	Automated Patient-Tailored Screening of the Liver for Diffuse Steatosis and Iron Overload Using MRI. American Journal of Roentgenology, 2013, 201, 583-588.	2.2	9

#	Article	IF	Citations
127	Dichorionic, diamnionic twin pregnancy discordant for anencephaly: Report of two cases and literature review. Radiology Case Reports, 2013, 8, 843.	0.6	0
128	Bone Marrow Enhancement During Time-Resolved Magnetic Resonance Angiography of the Pelvis. Journal of Computer Assisted Tomography, 2013, 37, 458-462.	0.9	0
129	The state of prostate MRI in 2013. Oncology, 2013, 27, 262-70.	0.5	32
130	Characterization of Adrenal Nodules With Dual-Energy CT: Can Virtual Unenhanced Attenuation Values Replace True Unenhanced Attenuation Values?. American Journal of Roentgenology, 2012, 198, 840-845.	2.2	103
131	Gradient Shimming During Magnetic Resonance Imaging of the Liver. Investigative Radiology, 2012, 47, 524-529.	6.2	5
132	MDCT Evaluation of the Pancreas: Nuts and Bolts. Radiologic Clinics of North America, 2012, 50, 365-377.	1.8	20
133	Diagnosis of Focal Nodular Hyperplasia With MRI: Multicenter Retrospective Study Comparing Gadobenate Dimeglumine to Gadoxetate Disodium. American Journal of Roentgenology, 2012, 199, 35-43.	2.2	55
134	Hepatocellular MR contrast agents: Enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine. European Journal of Radiology, 2012, 81, 2037-2041.	2.6	21
135	Hepatic hemangiomas: Difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium. European Journal of Radiology, 2012, 81, 2457-2462.	2.6	26
136	Liver MRI in the hepatocyte phase with gadoliniumâ€EOBâ€DTPA: Does increasing the flip angle improve conspicuity and detection rate of hypointense lesions?. Journal of Magnetic Resonance Imaging, 2012, 35, 611-616.	3.4	49
137	Functional evaluation of cystic duct patency with Gd-EOB-DTPA MR imaging: an alternative to hepatobiliary scintigraphy for diagnosis of acute cholecystitis?. Abdominal Imaging, 2012, 37, 457-464.	2.0	18
138	Contrast Enhanced Liver MRI in Patients with Primary Sclerosing Cholangitis. Academic Radiology, 2011, 18, 1549-1554.	2.5	21
139	Hepatobiliary transit times of gadoxetate disodium (Primovist®) for protocol optimization of comprehensive MR imaging of the biliary system—What is normal?. European Journal of Radiology, 2011, 79, 201-205.	2.6	39
140	PET Appearance of Tuberculous Empyema Necessitans. Clinical Nuclear Medicine, 2011, 36, 939-941.	1.3	1
141	Effect of Organ Enhancement and Habitus on Estimation of Unenhanced Attenuation at Contrast-Enhanced Dual-Energy MDCT: Concepts for Individualized and Organ-Specific Spectral Iodine Subtraction Strategies. American Journal of Roentgenology, 2011, 196, W558-W564.	2.2	27
142	Detection of Renal Lesion Enhancement with Dual-Energy Multidetector CT. Radiology, 2011, 259, 173-183.	7.3	91
143	Methodology to register prostate B-mode and ARFI images to MR and histology. , 2011, , .		1
144	Gadoxetate Disodium–Enhanced Hepatic MRI: Dose-Dependent Contrast Dynamics of Hepatic Parenchyma and Portal Vein. American Journal of Roentgenology, 2011, 196, W18-W24.	2.2	34

#	Article	IF	CITATIONS
145	Respiratory-triggered Three-dimensional T2-weighted MR Cholangiography after Injection of Gadoxetate Disodium: Is It Still Reliable?. Radiology, 2010, 255, 451-458.	7.3	24
146	Dynamic MR Imaging of the Biliary System Using Hepatocyte-Specific Contrast Agents. American Journal of Roentgenology, 2010, 195, 405-413.	2.2	50
147	Dual-Energy CT for Characterization of Adrenal Nodules: Initial Experience. American Journal of Roentgenology, 2010, 194, 1479-1483.	2.2	105
148	Dual-Energy Multidetector CT: How Does It Work, What Can It Tell Us, and When Can We Use It in Abdominopelvic Imaging? <sup></sup> . Radiographics, 2010, 30, 1037-1055.	3.3	333
149	<scp>d</scp> -Dimers and Efficacy of Clinical Risk Estimation Algorithms: Sensitivity in Evaluation of Acute Pulmonary Embolism. American Journal of Roentgenology, 2009, 193, 425-430.	2.2	40
150	Lisfranc Injury: Imaging Findings for this Important but Often-Missed Diagnosis. Current Problems in Diagnostic Radiology, 2008, 37, 115-126.	1.4	66
151	Trunk Kinematics and the Influence on Valgus Knee Stress in Persons With High Sacral Level Myelomeningocele. Journal of Pediatric Orthopaedics, 2005, 25, 89-94.	1.2	9
152	Feasibility of Ureteroscopic Lithotripsy and Renal Preservation in Patients with Non-functioning Kidney due to Isolated Ureteric Stone. Indian Journal of Surgery, $0, 1$ .	0.3	0